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Abstract 
The stilbene derivative, cis-3, 4’, 5-trimethoxy-3’-aminostilbene (stilbene 5c), is a potentially 
potent antitumor agent that acts via binding to the colchicine-binding pocket in microtubules. 
Earlier studies have shown that stilbene 5c induces cell death in ovarian cancer cells and 
leukemic cells (Lee RM et al, 2008; Lee RM et al, 2008). The present study was designed to 
investigate the effectiveness of this microtubule poison against the HCT-116 human colon cancer 
cell line and its mechanisms of action. Time course studies demonstrated that stilbene 5c 
produces a biphasic decrease in cell viability. The capacity of the cells to proliferate was not 
restored upon removal of the drug after 6 days of exposure. Consistent with the results of the 
time course studies, β-galactosidase staining indicated that treatment with stilbene 5c also 
promotes senescence. In addition to senescence, stilbene 5c-treated HCT-116 cells displayed 
formation of autophagic vesicles by acridine orange staining, which was supported by 
fluorescence-activated cell sorting (FACS). Further evidence of autophagy was derived from 
treatment of HCT116 cells carrying an RFP-LC3 construct with stilbene 5c, in which LC3 
puncta formation increased in a time-dependent manner. DAPI staining, TUNEL, and Annexin 5 
staining indicated that apoptosis is also occurring in stilbene 5c-treated HCT-116 cells. Cell 
cycle analysis demonstrated growth arrest at both G1 and G2/M, and an increase in the subG1 
population at days 3 and 5, which correspond to senescence and apoptosis respectively. 
Interestingly, DAPI and Hoechst staining revealed morphological changes in the cell nuclei 
(binucleated and micronucleated cells), which suggest that mitotic catastrophe may also serve as 
a mode of cell death after treatment with stilbene 5c. However, our studies indicated that stilbene 
5c works in a p53-independent manner. Exposure of P53-null HCT116 cells to stilbene resulted 
in a similar sensitivity as in p53-wild type HCT116 cells. We found that autophagic vacuoles 
were formed in response to stilbene 5c in p53-null HCT116 cells as well. Consistent with 
previous studies in other experimental cancer models, this work indicates that stilbene 5c could 
potentially be effective against colon cancer through the promotion of multiple modes of cell 
death. 
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Chapter 1: Introduction 
I. Cancer 
 
Cancer is a set of diseases that result from abnormal growth of cells. Under normal conditions, 
differentiated cells divide and grow in a controlled manner to replace aged and damaged cells. When 
regulatory molecular mechanisms fail to manage the progression and growth of cells, newly developed 
abnormal cells will invade and destroy the surrounding tissues. Those abnormal cells gather to form a 
mass called a tumor. However, it is not necessarily that all formed tumors are cancers. There are also 
non life-threatening benign tumors that can develop by unusual progression of cells. Benign tumors are 
generally slower growing than malignant tumors. Also, benign tumors do not have the propensity to 
destroy or invade the adjacent organs and tissues, which all malignant tumors do. Cancer can develop 
in different organs and tissues, forming different kinds of malignant tumors. Another critical 
characteristic of malignant tumors is their ability to spread throughout the body in a process called 
metastasis. Metastasis occurs when cells migrate via the circulation and travel through the blood stream 
to another site. In the process of metastasis, cancerous cells can cause severe damage to essential 
organs such as the liver, the lungs, and the brain. (American Cancer Society)  
II. Statistics  
 Cancer is a serious health problem in the United States as well as throughout the world. 
Annually, one out of four deaths in the United States is cancer-related, signifying a high rate of 
mortality [1]. In the United States, 1, 638, 910 new cases of cancer were expected to be diagnosed and 
577, 190 cases were anticipated to result in death[1]. The latest report has shown that there is a decrease 
in cancer incidence in different races and ethnicities during the last five years, especially in African 
American and Hispanics by 2.4% and 2.3%, respectively. Generally, cancers may be induced by natural 
radiation sources, environmental mutagens, viral infections, bacterial infections, fungal infections, and 
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failure of the immune system to prevent carcinogenesis. New reports indicated that colorectal cancer 
incidence is considered the third most common, as well as the third leading cause of death in both 
genders during the last few years. 
 
III. Colorectal Cancer  
Colon carcinoma, sometimes called colorectal carcinoma, represents one of the most common 
and life-threatening cancers worldwide.  Colorectal tumors are usually initiated by the development of 
noncancerous polyps in the tissues lining the colon. These developed polyps are subdivided into 
different kinds, and the polyps that most likely to develop into cancer are adenomatous polyps.  
According to the American Cancer Society (www.cancer.gov), colorectal cancer is considered the third 
most diagnosed cancer as well as the third leading cause of cancer-related deaths in both genders in the 
US in 2011. Statistically, 141,210 cases are expected to be diagnosed with colorectal cancer and 49,380 
deaths are caused by colorectal cancer. More than 20% of the cases presented in the clinic were late 
stage colorectal cancer which metastasizes to the liver. Typical therapeutic regimens for colon cancer 
include surgery, radiotherapy and chemotherapy. Although this type of cancer can be managed by 
surgery and/or chemotherapy, the late stages of colon cancer show high resistance to the current 
therapeutics. The first-line treatment of colon cancer includes a combination therapy of 5-flurouracil, 
leucovorin, and oxaliplatin or irinotecan with bevacizumab [2]. However, treatment of patients with 
currently used chemotherapeutic agents is associated with severe side effects due to their cytotoxic 
effects on normal proliferating and resting cells. Hence, searching for new effective anticancer agents is 
necessary to overcome these major side effects. 
 
IV. Microtubule inhibiting agents 
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One of the major chemotherapeutic agents used to treat cancer is a class of drugs that interfere 
with microtubule function and inhibit normal cell cycle progression. Traditionally, microtubule poisons 
are categorized into two major groups: drugs that cause stabilization of microtubules such as taxanes and 
epothilones and drugs that destabilize microtubules such as vinca alkaloids and colchicines [3].  These 
microtubules inhibitors can also be classified into three classes according to their binding sites on 
microtubules [4]. Vinca alkaloids, which include vincristine, vinblastine, and vinorelbin, are effective in 
the treatment of haematological malignancies. Paclitaxel and docetaxel belong to a group named taxanes 
that are commonly used to treat ovarian cancer as well as breast cancer. Colchicine-site inhibitors are 
considered the third group of tubulin-binding inhibitors. Although many agents have been discovered 
and classified in the group of colchicines-site inhibitors (CSI), none of these compounds have been 
clinically approved. CA4P, a phosphorylated form of combretastatin, and ZD6126 have been tested in 
phase I human clinical trials and phase II for combretastatin only [5]. Clinical trials of these agents have 
shown their propensity to work as vascular disrupting agents (VDAs); however, CSIs have shown 
serious side effects such as neurotoxicity and cardiovascular toxicity [6-8]. Therefore, development of 
new colchicine-binding inhibitors with fewer side effects is important to effectively improve the 
therapeutic impact of outcomes of colchicine-site inhibitors. 
 
V. Stilbene compounds 
Stilbene derivatives are a group of compounds that have established biological actions such as 
cell growth suppression and anti-vascular activities. A widely known agent of this group is trans-
resveratrol (trans-3, 4’, 5-trihydroxystilbene), a hydroxylated stilbene, that is found in grapes and 
possesses a beneficial effect in coronary artery disease [9]. Several studies have shown that resveratrol 
inhibits tumor cell proliferation in vitro and tumor vascularization in vivo leading to tumor growth 
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suppression [10]. Another example of biologically active stilbenes is combretastatin which is a natural 
cis-stilbene isolated from the South African tree Combretum caffrum. Previous studies have shown that 
combretastain has potent anticancer properties via binding to tubulin, which in turn causes endothelial 
cell damage and neovascular disruption [11]. The structures of these compounds have been modified by 
Simoni et al., to synthesize therapeutically active analogs of reservatrol by the addition and removal of 
functional groups on the basic chemical structure [12]. This work resulted in the synthesis of many 
different compounds with variable potencies. Stilbene 5c and 6c were identified as the most two active 
compounds among them.  
One of these newly developed compounds is cis-3, 4', 5-trimethoxy-3'-aminostilbene 
(stilbene 5c), a very potent inducer of tumor cell death via binding to the colchicine-binding 
pocket in microtubules [13]. This compound induces apoptosis in HL60 and U937 leukemic cells 
without producing cytotoxicity in normal haematopoietic progenitor cells at similar 
concentrations [14-15]. Also, stilbene 5c showed a very potent antitumor activity in SKOV3 
ovarian cancer cells at low concentrations [14]. In vivo and in vitro studies have proven that 
stilbene 5c does not affect normal perfusion but disrupts the tumor vascularization, showing high 
selectivity against cancerous cells [16]. Moreover, stilbene 5c has a relatively wide therapeutic 
index; in vivo studies of stilbene 5c have indicated that the neurotoxicity starts at 100 mg/kg 
without observing cardiac or bone marrow toxicity, while a dose of 25 mg/kg has shown a 
therapeutic effect against ovarian cancer in treated mice [14]. In addition, the pharmacokinetic 
studies of stilbene 5c in tumor xenograft model indicated that the drug has an average half-life of 
1.8 hours, Cmax 2,302 ng/mL and clearance 32.9 L/h [16]. In this study, the concentration of 
stilbene 5c was detected in brain, liver, spleen, heart, lung, kidney and plasma. Stilbene 5c levels 
were undetectable in lung, heart and spleen at 1 hour after the injection, but levels of stilbene 5c 
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in brain, liver and kidney were determined at 1 hour and significantly decreased 3 hours post 
injections. On the other hand, stilbene 5c was maintained accumulated in both plasma and tumor 
cells.  
Stilbene 5c is thought to induce its anticancer effect in a cell cycle-dependent pathway since the 
drug is a microtubule poison. Stilbene 5c has been shown to block the progression of the cell cycle at the 
G2/M phase in several cell lines at low concentrations, while cell death was seen at higher doses [14].  A 
previous study indicated that stilbene 5c enhances the production of reactive oxygen species (ROS) 
through disturbing electron transport chain complex in mitochondria, which ultimately leads to cell 
death [14].  
  
VI. Responses to drug treatment 
1) Apoptosis  
Apoptosis was first defined in 1972 by Kerr, Wyllie, and Currie to explain the 
characteristic aspects of programmed cell death [17]. It is a mode of cell death that takes place 
throughout the development as well as the growth and the aging of an organism. Apoptosis is 
considered to serve as a protective mechanism and healthy process that regularly occurs in living 
tissues to maintain the number of normal cells in that system in response to exposure to harmful 
signals or disease insults [18]. The morphological aspects of the dying cells have been 
differentiated between cells undergoing apoptosis and cells in necrosis. Unlike necrosis, 
apoptosis results in the reduction of cell size, cell nucleus, and rupture of nucleus and its 
chromatin, while oncotic necrosis is characterized by swelling and karyolysis [19].  Also, 
apoptosis is a controlled and energy-dependent cell death, which can occur in individual cells as 
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well as group of cells, whereas necrosis is a passive and uncontrolled process that can be due to 
e.g. a nonspecific injury to the cell membrane.  
There are two types of apoptosis: physiologic and pathologic apoptosis. Either in 
physiological or pathological conditions, apoptosis can result from different types of stimuli 
affecting cellular signaling mechanisms and lead to a consequential cell death. It appears that 
apoptosis is a cell type specific process; that is some cell types are resistant to certain stimuli, 
while other cells may interpret the same stimuli as a trigger for death pathway induction. 
Physiologic apoptosis is an essential phenomenon that has been characterized in many human 
systems through developmental stages and adulthood in normal and disease states such as in the 
immune and nervous systems to kill pathogen-infected cells and overproduced cells [20-21].  
 Molecular mechanisms of programmed cell death are explored and well known. 
Apoptosis is an irreversible mode of cell death that involves caspase activation inside the cell 
and ends by engulfment of the apoptotic cell by macrophages. The process of apoptosis is 
composed of three phases that include initiation, effector, and degradation, where markers of 
apoptosis can be clearly identified. During this process, pro-apoptotic proteins stimulate 
upstream caspases to activate downstream effector caspases.  Caspase cleavage leads to DNA 
cleavage by endogenous DNases that cut double strand DNA into fragments [22].  
Apoptosis can be triggered by extrinsic and intrinsic pathways, where the former utilizes 
death ligand-death receptor binding, and the latter can be triggered by toxins or radiation. The 
extrinsic pathway involves the activation of a death receptor from the tumor necrosis (TNF) 
superfamily e.g. TRAIL. By activation, the adaptor molecule Fas-associated death domain 
(FADD) recruits caspase 8 and then initiates apoptosis via the cleavage of caspase 3 or 7.  The 
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intrinsic pathway is generally triggered by the release of cytochrome c, smac/DIABLO, or 
apoptosis inducing factor (AIF) from the inner membrane of mitochondria. When a stress signal 
is initiated, those released mitochondrial proteins activate effector caspases and lead to 
subsequent DNA fragmentation [22].  
It is noteworthy to mention that apoptosis plays a major role in various diseases. 
Dysregulations of programmed cell death is considered pathologic apoptosis that leads to many 
diseases such as cancer, autoimmune lymphoproliferative syndrome, AIDS, ischemia, and 
neurodegenerative diseases like Alzheimer’s disease and Huntington’s disease. Therefore, it is 
important to understand the molecular basis of apoptosis either to achieve a therapeutic effect of 
a drug or to better know how biological systems respond to abnormal cell division.  
2) Autophagy  
Autophagy is a biological process that is induced upon nutrient deprivation and/or 
cellular stress. During autophagy, intracellular and extracellular nutrients are sequestered into 
autophagosomes and transported to the lysosomes to be degraded, recycled, and then reused by 
the cell. Autophagy plays key roles in regulation of cellular homeostasis by breaking down old 
or misfolded proteins, maintaining the viability of starving cells by producing amino acids, and 
protecting cells against pathogenic infections by the engulfment of a pathogen [23-25]. Cells 
that undergo autophagy are characterized by enlargement and swelling of nuclei with formation 
of acidic vacuoles. Although the role of autophagy is still debatable, several reports indicated 
that autophagy is a protective process induced to maintain cellular viability in response to 
harmful insults [26-28].  
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Promotion of autophagy is highly regulated by different genes and advances through 
several steps: induction, autophagosome nucleation, and completion, by which formed 
autophagosomes fuse with lysosomes for protein breakdown [29]. During the first phase, the 
Atg1 complex, which includes Atg1, Atg13, and Atg17 as well as other factors, is activated to 
initiate autophagy [30]. Then, class-III phosphatidylinositol-3-kinase (PI3K) and Beclin-1/Atg6 
activation is required to collect parts of cytoplasm and other organelles and build up a double-
membraned autophagosome. After that, LC3 protein is cleaved by Atg4 protease and lipidated by 
phosphatidylethanolamine (PE) via Atg7 and Atg3 proteins to form LC3-PE. Following LC3 
cleavage, the Atg12/Atg5/Atg16 complex regulates the binding of LC3-PE to the 
autophagosomal membrane [31-33]. Finally, formed autophagosomes unite with acidic 
lysosomes, which results in the decomposition of autophagosomes-sequestered proteins [25-26].  
An important regulator protein of autophagy is the mammalian protein kinase mTOR, 
which is the target of rapamycin. mTOR protein is a serine/threonine kinase that is activated 
under healthy growth conditions and induces gene translation and synthesis of necessary 
proteins. During starvation and nutrients deprivation, the mTOR pathway becomes inactivated 
and autophagy is promoted [34]. Also, PI3K pathway functions upstream of mTOR to contribute 
to autophagy induction [35-36]. This pathway is shown to be activated due to nutrient 
deprivation but not in response to conventional chemotherapy. Therefore, it could be valuable 
studying the activation of these pathways by the effects of microtubule inhibitors. 
 
3) Senescence  
Senescence is considered to be an irreversible growth arrest of cells. During senescence, 
the cells’ shape and morphology become flattened and enlarged with decreased pH and enhanced 
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β-galactosidase activity [37]. Generally, senescent cells show resistance against mitogenic and 
apoptotic signals [38]. Senescence occurs as a result of oncogenic stress, DNA damage, or 
cytotoxic drugs [39]. However, irregular senescence is associated with the development of 
certain diseases such as atherosclerosis, osteoarthritis, muscular degeneration, ulcer formation, 
Alzheimer’s dementia, diabetes, and immune exhaustion [40]. On the other side, defective 
signaling pathways of senescence may lead to unlimited growth of cells, which may ultimately 
form a tumor. The ability of these cells to become immortal results from the fact that cancer cells 
are capable of escaping from the regulated lifetime of somatic normal cells. Thus, cellular 
senescence is thought to be a tumor suppressing process as it stops infinite cellular divisions 
[41].  
To determine a finite number of cell divisions, the term “Hayflick limit” is used as a 
reference for how many times a normal cell will divide. Every chromosome has a structure at the 
end of its DNA called the “Telomere” which contain repeat of the sequence TTAGGG [42-43]. 
The telomere is not replicable, and therefore becomes reduced after each cell division. The 
decrease in telomere length eventually limits the ability of cells to divide. Therefore, the 
reduction in telomere length is considered as an important factor in the regulation of replicative 
senescence [44]. 
Senescence can be induced via many pathways [40], but the two major pathways that are 
involved in senescence are: p14ARF/p53/p21 pathway and the INK4/CDK/pRb pathway [45]. In 
the first pathway, the protein p14ARF negatively regulates MDM2, which originally 
ubiquitinates p53, and thus causes activation of p53 [46]. Consequently, the p53 protein acts 
upstream of a CDK inhibitor p21, leading to growth arrest and senescence [47]. Also, p53 has 
other downstream targets to promote cellular senescence such as 14-3-3 and GADD45 that 
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inhibit G2/M transition and downregulation of myc [48]. In the pRb-dependent pathway, 
senescence-inducing signals activate p16INK4a that inhibits the function of CDKs. The pRb 
protein is known to be inactivated by CDKs; consequently, p16INK4 activation promotes Rb 
dephosphorylation and Rb activation to bind to members of the E2F family of transcription 
factors, which results in cellular senescence [49-50]. Furthermore, there is a cross-talk between 
these two pathways. The protein p21, which is upregulated by p53, promotes senescence either 
directly by the first pathway or through the inhibition of CDK in the second pathway [51].  
Senescence can be telomere-dependent or –independent.  Telomeres are gradually lost in 
each S phase of cell cycle, resulting in loss of DNA at the very end of chromosomes. Also, some 
cells lack the ability to reactivate telomerase, the enzyme responsible for the addition of DNA 
sequence repeats at the end of chromosomes [52-53]. Existence of erosions at telomeric sites 
leads to the generation of a persistent DNA damage response and growth arrest [54-56]. In 
addition, nontelomeric DNA breaks can induce senescence and growth arrest via persistent DNA 
damage response [57].  
Senescence can also occur independently of the DNA damage response. Several reports 
have indicated that p21WAF1 and p16INK4a can induce cells to undergo senescence with no 
DNA damage response [55, 58]. A kind of stress called “Culture shock’’ induces senescence 
with no erosions of the telomeres [59]. This group of stresses includes hyperphysiological 
oxidation and the presence of serum instead of plasma. Furthermore, loss of Pten phosphatase 
also causes growth arrest of cells without induction of the DDR signaling pathway [60].  
Although stilbene 5c is not a DNA damaging agent like some anticancer drugs and 
ionizing radiation, it could induce senescence through the activation of some tumor suppressor 
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genes. Many reports indicated that some microtubule poisons lead to cell division failure 
accompanied with activation of check points [61-62]. Therefore, it is worthy to study whether 
stilbene 5c promotes senescence in HCT116 colon carcinoma cells.  
4) Mitotic catastrophe  
Mitotic catastrophe is a term used to describe a mode of cell death resulting from 
dysregulated mitosis, usually resulting in the formation of cells with multiple nuclei. During 
mitotic catastrophe, clusters of aneuploidy and missegregated chromosomes are formed and 
enclosed within the nuclear envelope. The formation of the nuclear envelope results in the 
enlargement of treated cells with the presence of multiple micronuclei, as a distinct feature of 
mitotic catastrophe. Also, mitotic catastrophe induction can be determined through the 
expression of mitosis-related genes. This faulty mitosis occurs as a result of disconnection 
between the phase of DNA replication and mitosis during cell cycle progression. Thus, it is still 
controversial whether mitotic catastrophe is a mode of cell death or a phenomenon that leads to 
cell death via apoptosis or necrosis [63]. It is worth mentioning that cancer cells need to escape 
apoptosis to develop malignancy. Despite the differences between mitotic catastrophe and 
apoptosis, several reports have shown that drug-induced mitotic catastrophe is associated with 
the release of pro-apoptotic proteins and activated caspases, indicating similarity in signaling 
pathways, or at least a cross-talk between apoptosis and mitotic catastrophe [64-66]. Many 
reports have shown that mitosis-regulating proteins have been changed in response to antitumor 
drugs, thus leading to an aberrant mitosis and nuclear division [67-69]. The clinical significance 
of mitotic catastrophe as a mode of cell death is derived from evidence of mitotic catastrophe 
formation beside other modes of cell death in cancer patients treated with antitumor drugs [67, 
70-71]. Several anti-microtubule agents such as vinca alkaloids and taxanes have been shown to 
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promote mitotic catastrophe probably by mitotic spindles distruption [71-72]. Given the fact that 
stilbene 5c is a microtubule poison, it is important to address whether this drug induces mitotic 
catastrophe in HCT116 cells.  
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Chapter 2: Materials and methods 
2.1 Cell culture  
 HCT-116 colon cancer cells were purchased from ATCC and maintained in 10% DMSO 
(Sigma Chemical, St. Louis, MO) with Fetal Bovine Serum (FBS) (GIBCO Life Technologies, 
Gaithersburg, MD) and stored frozen in liquid nitrogen until ready for use. Cells were defrosted 
and cultured in a T75 flask (Cellstar) in RPMI 1640 medium with 5% fetal bovine serum, 5% 
bovine calf serum, 2 mM L-glutamine, and penicillin/streptomycin 0.5 mL/100 mL medium 
(10,000 units/mL penicillin and 10 mg/mL streptomycin (GIBCO Life Technologies, 
Gaithersburg, MD) and incubated at 37ºC, 5% CO2, in a moisturized environment. When cells 
reach 80% confluency, cells are washed with 1X PBS (GIBCO) and harvested by 0.25% trypsin-
EDTA (GIBCO) (incubation for 5 minutes). Trypsin is deactivated by addition of 5 mL of 
serum-containing RPMI 1640, cells are collected and centrifuged at 1,500 rpm for 5 minutes. 
Media and trypsin are removed and 5 mL of new sterile medium is added to the pellet; cells are 
resuspended and 500 µL of suspension is placed into 96 mm³ plate filled with 10 mL of RPMI 
1640 medium. In every experiment, cells are cultured under identical conditions and incubated 
overnight to allow for adherence before treatment with continuous drug exposure. Stilbene 5c 
preparations were kindly provided by Dr. Ray Lee’s laboratory at Virginia Commonwealth 
University. Drug was diluted in autoclaved DMSO (Sigma Chemical, St. Louis, MO) aliquots at 
concentrations of 30 mM and 300 µM. Used drug was not thawed more than twice due to the 
stability of the drug. 
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2.2 Clonogenic Survival assay 
 The ability of cells to form colonies was evaluated by plating 200 cells in 6-well plates 
for control,1% DMSO, 10 nM of stilbene 5c, and 30 nM of stilbene 5c, and 2000 cells for 100 
nM of stilbene 5c, 300 nM of stilbene, and 600 nM of stilbene 5c. Cells were permitted to adhere 
for overnight. The next day, cells were treated with the indicated concentrations for 2 days, drug 
was removed and fresh media was added every other day. At day 9, cells were washed one time 
with 1X PBS before fixation with 100% of methanol for 10 minutes. Methanol was aspired and 
colonies were stained with crystal violet dye (1%) in deionized water for 10 minutes. Colonies 
were counted visually in each well.  
2.3 MTT dye assay for cell viability 
In 96-well plates, 200 µL of medium containing 6000 cells was added to each well and 
left to attach overnight prior to drug treatment. After 72 hours of drug exposure, media was 
aspired and MTT solution (2 mg/mL PBS made up in the dark) was added to each well and 
incubated at 37ºC for 3 hours. The MTT dye becomes reduced to insoluble formazan inside 
living cells. 100 µL of DMSO was added for 5 minutes to each well to dissolve the blue dye. 
Absorbance was read at 490 nm (KC Junior software, EL800 Universal Microplate Reader).  
2.4 Time course of drug toxicity and its impact on cell viability  
 Cells were cultured in 6-well plates in equal number and left overnight for attachment. 
The next day, cells were treated with drug and the number of viable cells was counted on daily 
basis for 5 days. At every time point, drug was removed and cells were washed one time with 1X 
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PBS. Then, 350 µL of 0.25% trypsin was added to every well for harvesting and incubated for 5 
minutes, then deactivated by 650 µL of fresh media, to make up 1 mL of cell suspension. Cells 
were collected in 1 mL conical tubes (Eppendorf) and 10 µL of cell suspension was added to 10 
µL of trypan blue and injected in chamber slides (invitrogen) and counted using Countess 
Machine (invitrogen). A compromised cell membrane will allow trypan blue to penetrate inside 
the cell, indicative of loss of viability. 
2.5 Assessment of apoptosis by DAPI staining 
 At indicated time points, both adherent and non-adherent cells were collected and 
centrifuged at 1,500 rpm for 5 minutes. Medium was removed and cells were resuspended in 1 
mL of fresh medium. Cells were then diluted to 40,000 cells in 200 µL of 1X PBS and the same 
volume was loaded per slide. Prepared slides were spun at 3,000 rpm for 5 minutes (Shandon 
Cytospin 4, Thermal Electron Corp). Slides were kept in refrigerator until ready for experimental 
use. At the day of staining, cells were fixed at room temperature with 4% formaldehyde in 1X 
PBS for 10 minutes. Slides were then rinsed in 1X PBS for 10 minutes. Acetic acid was diluted 
in ethanol (1:2 dilution) and used to fix cells at 20ºC for 5 minutes and then washed with 1X PBS 
for 5 minutes. 10 µL of Vectashield:Dapi (1:1000 dilution) was prepared and added to every 
slide. Nail polish was used to seal slides with cover slips. Images were taken using an Olympus 
1X 70 microscope and an Olympus SC 35 type camera. Three different experiments were 
visualized and assessed.  
2.6 TUNEL assay for apoptosis 
 Another method of assessments of apoptosis is by detecting DNA fragmentation via 
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL). For this assay, cells 
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were harvested and collected at various time points and centrifuged at 1,500 rpm for 5 minutes. 
Medium was removed and cells were resuspended in fresh media. A dilution of 40,000 cells in 
200 µL per slide was prepared and cells were spun at 3,000 rpm for 5 minutes (Shandon 
Cytospin 4, Thermal Electron Corp). Slides were kept refrigerated at 4ºC until ready for use. On 
day of staining, cells were washed with PBS and then fixed with 4% formaldehyde in PBS for 10 
minutes at room temperature.  Cells were then washed twice with PBS for 5 minutes and fixed 
with 1:2 of acetic acid and ethanol for 5 minutes at 20ºC, and washed again with PBS. 
ImmunoPen was used to surround cells and hold solutions. After that, cells were blocked with 
BSA diluted in PBS in a ratio of 1 mg/ml for 30 minutes. Slides were rinsed twice in PBS and 
enzyme mixture composed of 5X buffer, terminal transferase, 25mM CoCl2, fluorescein-12dUTP 
and deionized water, was added for staining for an hour in incubator. After two washes with 
PBS, slides were topped with cover slips and images were taken under the flourescenct 
microscope. The same slides could be used for DAPI staining by mounting with Vectashield: 
DAPI (1:1000) before cover slips.  
2.7 Annexin 5-PI staining for apoptosis 
 In cells undergoing early apoptosis, phosphatidyl serine (PS), which is originally located 
in the inner cell membrane, transfers to the outer cell membrane. Translocated phosphatidyl 
serine (PS) can be bound with Annexin V attached to a fluorescent chromophore (FITC) to 
identify early apoptosis. Propium iodide (PI) penetrates non-intact cellular membranes and stains 
cells, serving as a marker of late apoptosis or necrosis. In this experiment, cells were plated 
overnight to permit cells to adhere. On the following day, cells were treated with the drug. At 
several time points, adherent and non-adherent cells were harvested by 0.25% trypsin and 
centrifuged at 2,000 rpm for 5 minutes. Cells were then resuspended in 1 mL of 1X PBS, 
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transferred to 2 mL tubes, and centrifuged at 2,000 rpm for 5 minutes. PBS was removed and 
100 µL of 1X binding buffer (BD Biosciences) was added to pellets per tube. 5 µL of Annexin-
FITC (BD Biosciencec) and 5 µL of PI at 10 µg/mL (BD Biosciences) were then added per tube. 
In the dark, cells were softly vortexed and incubated for 15 minutes at room temperature. Before 
anaysis by flow cytometry, 400 µL of 1X binding buffer was added per tube and samples were 
analyzed by flow cytometry technique as soon as possible to measure the fluorescence at 530 
nM.  
2.8 Hoechst Staining for mitotic catastrophe  
 Both adherent and non-adherent cells were both harvested at indicated time points and 
centrifuged at 1,500 rpm for 5 minutes at 5ºC. Supernatant was removed and the cell pellet was 
resuspended in 5 mL of PBS diluted to 40,000 cells in 200 µL, and refrigerated. On the day of 
staining, cells were fixed with 0.075 M KCL for 8 minutes at room temperature, and then 
washed with 1X PBS. A 1:3 dilution of methanol and glacial acetic acid was prepared and slides 
were rinsed in solution for 20 minutes and then washed with deionized water and allowed to dry 
overnight. Cells were stained with Hoechst dye of 2 µM in nanopure water for 10 minutes and 
slides were topped by cover slips and images were taken by the same tools as for DAPI and 
TUNEL. Mitotic catastrophe was evaluated according to the formation of bi- and micronucleated 
cells.   
2.9 Evaluation of autophagy by acridine orange staining  
200,000 cells were seeded in 6-well plates and permitted to adhere overnight and drug-
treated the next day. At various time points, drug was removed and cells washed once with 1X 
PBS. Acridine orange dye was diluted in PBS in a ratio of 1:10000 (prepared in the dark) and 
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added to cells for staining, and incubated for 15 minutes. Dye then was aspired and plates were 
washed with 1X PBS and fresh medium was added. Photographs were taken with an Olympus 
1X 70 microscope and an Olympus SC 35 camera.  
2.10 Transfection of HCT116 cells with RFP-LC3 
             The Tolkovosky laboratory has generated the RFP-LC3 construct [73]. Frozen 
cells were thawed, centrifuged, placed in a fresh medium, and passaged many times before 
transfection. 1x10 6 cells were collected in a pellet and resuspended in 100 µL of the 
Nucleofector V mix (Nucleofector kit V, Amaxa). A microgram of the RFP-LC3 vector was 
added to the suspension. The whole entire suspension was transferred to a cuvette, which then 
was placed in the nucleofector device to run program D-32 and transfect the cells. Transfected 
cells were then mixed with 500 µL of warm medium and transferred to a Petri dish. Gentamycin 
8ng/mL was used to maintain a stable transfection.  
2.11 Measurement of acridine orange staining by flow cytometry for autophagy  
 Flow analysis was utilized to count the cell population positively stained with acridine 
orange. Treated cells were harvested, collected, and centrifuged at speed of 1500 rpm. 
Supernatant was removed and pellets were resuspended in 1 mL of fresh medium. Cell 
suspension was filtered through standard flow cytometry 40 micron filter (BD falcon). A 
10:1000 dilution of acridine orange in 1X PBS was prepared (in the dark) and protected from 
light until ready for use. At flow cytometry, 10 µL of acridine orange solution was added to per 
sample to make the dilution of 1:10000. When analyzed by flow cytometry, the acridine orange 
dye is excited at wavelength 525 nM for green flourescence and 620 nM for red fourescence. 
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2.12 Senescence by β-Galactosidase staining 
 Detection of senescence was by β-Galactosidase staining after exposure to the drug 
treatment. Cells were washed once with 1X PBS and fixed with 2% formaldehyde/ 0.2% 
glutaraldehyde for 5 minutes. Fixing solution was aspired and PBS was used again to wash and a 
staining solution composed of 1 mg/mL 5-bromo-4-chloro-3-inolyl-β-galactosidase in 
dimethylformamide (20 mg/mL stock), 5 mM potassium ferricyanide, 150 mM NaCl, 40 mM 
citric acid/sodium phosphate, 2 mM MgCl2, at pH 6.0 was added and the cells were incubated 
overnight at 37ºC. The following day, cells were washed twice with PBS and pictures were 
taken.  
2.13 Quantification of β-Galactosidase staining using flow cytometry for senescence 
 On the day of staining, old media was washed out and 100 nM of bafilomycin A1 in fresh 
media was added to the treated cells to induce lysosomal alkalinization and left incubated at 37ºC 
and 5% CO2 for 1 hour. After incubation, C12FDG working solution was added to each well in 
amount to make the final concentration 33 µM and was continued incubation for another 1 hour. 
Media was then aspired and cells were washed twice with PBS. Cells were harvested and 
collected for centrifugation at speed 1500 rpm and resuspended in PBS. C12FDG is a substance 
that hydrolyzed by upregulated β-galactosidase enzyme and becomes fluorescent at wavelength 
of 500–510 nM. 
2.14 Cell cycle analysis 
Cells were seeded overnight to adhere. The next day, supplemented medium was 
removed and serum depleted medium was added and left for 24 hours to synchronize all cells at 
the same phase. On day 0, cells were treated with stilbene 5c. At the indicated time points, viable 
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and non-viable cells were harvested and collected. Cells were centrifuged at 1500 rpm and 
supernatant was aspired. Pellets were resuspended in PBS for wash and centrifuged at 1500 rpm 
again. After removing supernatant, 0.2 mL of PBS was added and pellets were resuspended very 
well in order to obtain a single cell suspension. 1.8 mL of cold 70% ethanol was added gradually 
per tube into the cell suspension and vortexed very well. Cell suspensions were stored at 4ºC 
until ready for use. On day of staining, cells were centrifuged from ethanol and PBS was added 
for wash. PBS was removed and staining solution was added to the pellets 2 hours prior to flow 
cytometry. Staining solution contains 0.1% (v/v) Triton-X-100 in 10 mL PBS, 2 mg of DNase-
free RNase A, and 0.2 mL of the propium iodide stock (1 mg/ml).  
2. 15 Assessment of antitumor effect of stilbene 5c in vivo 
 B16F10 melanoma cell line is murine malignant tumor cells that can be injected in the 
C57BL/6 mouse to form a syngeneic model. This cell line was chosen for its ability to 
metastasize into the lungs. In this study, mice were injected with 1x105 tumor cells/mouse on day 
29. In the following day, mice were intraperitoneally injected with the drug once a day, five days 
a week, for two weeks.  The drug was diluted in a vehicle containing Tween, Ethanol, and saline 
in a ratio of 2:1:7 respectively. Sentinel mice were used to monitor the formation of tumor 
nodules onto the lungs. At certain time point, mice were sacrificed and the lungs were removed 
and saved in Bouin’s solution, a common fixative solution used to preserve tissues. The tumor 
burden in mice was assessed based on two parameters. The first parameter is the visual counting 
of how many black nodules have been formed in each lung. The second parameter was used is 
the calculation of the surface area of each nodule. Measurement of the latter parameter was 
performed by embedding lung tissues into paraffin, sectioned at 4 microns thickness and stained 
with Hematoxylin and Eosin. Images of stained nodules were taken under the microscope and 
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the surface area of each tumor nodule was calculated using Nanozoomer computer software 
(Olympus). 
2. 16 Western blotting  
 In order to determine whether some proteins were induced, degraded, or downregulated, 
we conducted a specific assay to analyze protein levels. After the indicated time points, we 
collect viable and non-viable cells in a pellet. These collected cells were mixed with 100 to 200 
µL of 1X Tris lysis buffer (1 M Tris (pH 6.8), 10% SDS, and dH2O) containing protease 
inhibitors and boiled for 5 minutes. Protein concentration was measured using the Bradford 
protein assay (BioRad) and 40 µg of total cell lysate was separated in a 12% gel using SDS-
PAGE. Proteins were transferred onto nitrocellulose membrane for 1.5 hours and washed 3 times 
with PBS containing 0.01% Tween for 5 minutes in each time. Membrane was blocked for one 
hour with TBS-Tween 20 buffer containing 5% nonfat dry milk. The proteins were then blocked 
with the primary antibody and left overnight in 4ºC. In the following day, the primary antibody 
was washed out and the immunoflourescent secondary antibody was added for an hour at room 
temperature. Membrane was washed three times and bands were detected using enhanced 
chemiluminescence detection reagents from Pierce (Rockford, IL). 
2. 17 Statistical analysis  
 Statistics were performed using ANOVA followed by post-hoc analysis. The significance 
of group values was determined based on a p-value of p<0.05.  
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Chapter 3: Results 
 
3.1 Stilbene 5c produces growth arrest and cell death in HCT116 colorectal cancer cells.  
Previous reports have shown that stilbene 5c was effective in promoting cell death and 
growth arrest at nanomolar concentrations, 30 nM and 100 nM, showing high potency against 
both leukemic and ovarian cancer cells [8-9]. Figure 1 show that continuous exposure of 
HCT116 cells to 0, 30, 100, 300, and 600 nM of stilbene 5c for 72 hours resulted in reduced 
numbers of viable cells in a dose-dependent manner, with a significant cell viability decrease at 
100 nM, 300 nM, and 600 nM by approximately75%, 80%, and 84%, respectively. Consistent 
with our observation in the MTT assay, treatment of HCT116 colon carcinoma cells with 
stilbene 5c for 48 hours with the same indicated concentrations resulted in a 90% decline in 
colony formation starting at 100 nM (Figure 2). This concentration is relevant to the plasma 
concentration that has been shown previously in the pharmacokinetic studies of stilbene 5c in 
mice [16]. Based on these findings, we have chosen to continue our work with 100 nM as our 
effective concentration to further investigate the mechanisms of drug’s cytotoxicity. In order to 
understand whether stilbene 5c induces cell killing or growth arrest, we assessed the effects of 
stilbene 5c on cell viability over a period of five days in a time course study. Figure 3 
demonstrates a decrease in number of viable cells in a time course treatment when exposed to 
100 nM stilbene 5c. Twenty-four hours post treatment, extensive cell death was observed in the 
treated groups. Thereafter, the treated tumor cell populations showed an apparent prolonged 
growth arrest. To assess whether treated HCT116 cells were able to recover their capacity to 
proliferate, drug was washed out on day 5 and fresh medium was added and replaced every other 
day for an additional 10 days. These experiments demonstrate that the residual surviving tumor 
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cell population had lost its capacity to recover, pointing toward an irreversible growth arrested 
state. 
3.2 Induction of irreversible senescence and loss of proliferation  
In previous studies, UCI-101 and SKOV3 ovarian cancer cells and HL60 and U937 
leukemic cells displayed a growth suppression and cell cycle arrest at G2/M upon treatment with 
stilbene 5c [8,9]. In our time course study, cells treated with 100 nM of stilbene 5c have shown 
cell death followed by growth arrest during days 2, 3, and 4. In addition, residual cells did not 
show proliferative recovery after drug removal by 10 days (Figure 4). Therefore, we decided to 
determine whether senescence was promoted in response to the treatment with stilbene 5c. β-
galactosidase staining was performed 72 hours post treatment and visualized by microscopy. 
Treated groups showed morphological markers of senescence such as granulations, flattening, 
and spreading of cells. Also, the treated cells demonstrated positive staining with bluish green β-
galactosidase color (Figure 5). The intensity of β-galactosidase staining was further quantified by 
flow cytometry technique on days 2 and 4 (Figure 6A). A significant fraction of the treated cell 
populations was apparently shifted to the area of positive staining with a rightward move of the 
histogram peak on day 4, but not on day 2. In addition to the quantification of β-galactosidase 
staining, flow cytometry technique also was used to measure the size of cells. Treated HCT116 
colon carcinoma cells on days 2 and 4 were remarkably enlarged compared to control (Figure 
6B), showing consistency with our microscopic observations. Taken together, senescence was 
initiated in HCT116 cells as early as 48 hours after initiating the treatment with stilbene 5c.  
 
3.3 Promotion of autophagy by Stilbene 5c in HCT116 cells 
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 Autophagy is a regulated process in which misfolded proteins and damaged cellular 
components are broken down by lysosomal enzymes in double-membrane enclosures. Some 
literature reviews and studies indicate that extensive autophagy is defined as type II programmed 
cell death. However, a recent study showed that the process of autophagy is an important 
mechanism that leads to senescence [74]. In addition, previous studies from our laboratory 
demonstrated that autophagy and senescence were induced in HCT116 cells in response to 
another colchicine site-binding inhibitor, JG-03-14. Since stilbene 5c induced senescence in 
HCT-116 colon carcinoma cells, we then sought to establish whether senescence might be 
preceded by autophagy. A number of different approaches and tools including acridine orange 
staining, RFP-LC3 redistribution, and p62 degradation were utilized to address this question.  
 During autophagy, acidified autophagosomes fuse with lysosomes to form acidic 
vacuoles, which are stainable by acridine orange dye.  Figure 7 shows that control HCT-116 cells 
have a single orange circle per cell located approximately in the same site in the cytoplasm, 
indicating a relatively high basal level of autophagy that may be induced in HCT-116 cells due to 
activated ras protein [75]. Cells treated with 100 nM of stilbene 5c displayed different large 
number of stained vacuoles per cell that increased in a time-dependent manner. In addition, cells 
exposed to 100 nM of stilbene 5c became enlarged in comparison with control cells, 
demonstrating a morphological sign of autophagy. An additional flow cytometry technique used 
to evaluate autophagy in cells based on the intensity of acridine orange staining was used in our 
studies. In this experiment, we found that treated cells showed a significant increase in the 
percentage  of the cell population falling into the area red-fluorescing cells (5.3 ± 3.03 with 
control, 25.07 ± 6.26 with treatment; p<0.05), indicating cells undergo autophagy when treated 
with stilbene 5c (Figure 8).  
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 We also monitored the localization of the LC3-II protein in HCT116 colon carcinoma 
cells.  LC3-I is a cytoplasmic protein that converts to LC3-II when lipidated and binds to 
autophagosomal membranes during autophagy. On days 1, 2, and 3, RFP-LC3 - transfected 
HCT-116 cells were visualized by flurescent microscopy. As shown in figure 9, promotion of 
autophagy was confirmed by RFP-LC3 redistribution. Whereas control cells show one small 
diffuse fluorescent punctuate per cell, red puncta were clearly increased and distributed in the 
treated cells.  
 Autophagic flux was also measured via p62 degradation, a protein sequestered in 
autophagosome and degraded by lysosomal hydrolases [76]. HCT116 colon cancer cells treated 
with 100 nM stilbene 5c were tested for p62 decomposition by immunoblotting. Level of p62 
clearly declined 48 hours post treatment (Figure 10).  
 
3.4 Evaluation of apoptotic cell death induced by stilbene 5c 
 One of the desirable outcomes of therapeutic treatment of cancer is the promotion of 
apoptosis. We evaluated apoptosis in HCT116 cells in response to 100 nM of stilbene 5c via 
different assays including DAPI staining, TUNEL assay, and Annexin V-PI staining. Even 
though we observed cell death during the first day in our time course study, we failed to find any 
evidence of apoptosis 24 hours after the treatment with stilbene 5c in our annexin V–PI staining 
experiment (Figure 12). Dramatically, a significant part of the treated cell population shifted 
toward early and late apoptosis on days 3 and 5 (4.2 ± 3.63 with control, 3.533 ± 0.321 with Day 
1, 19.6 ± 4.6 with Day 3, 19.6 ± 1.77; p<0.05 control versus Day 3 and Day 5). To confirm the 
induction of apoptotic cell death in cells treated with stilbene 5c, we stained cells with DAPI and 
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TUNEL to characterize apoptosis markers under the fluorescent microscope. Although DAPI 
staining barely shows nuclear shrinkage or distortion in treated groups, TUNEL images for the 
same samples presented fluorescence of fragmented DNA, indicating that HCT116 cells undergo 
apoptosis upon drug treatment (Figure 11).  
 
3.5 Assessment of mitotic catastrophe by stilbene 5c 
 In addition to apoptosis, there is another form of aberrant mitosis – caused cell death 
known as mitotic catastrophe. Several reports have shown that mitotic catastrophe might 
characterize a mitotic form of apoptosis [65, 77]. In our assessment of apoptosis markers by 
DAPI staining, we found that some cells have abnormal nuclear morphology that was obviously 
enlarged with multipolar structure. We then plated HCT116 cells in 6-well plates and treated 
them with 100 nM stilbene 5c. Cells were then stained directly with DAPI while they were in the 
plates. Images of DAPI confirm mitotic arrest in treated cells as shown by the appearance of 
more than a single nucleus in one cell (Figure 13). Therefore, we performed another experiment 
called Hoechst staining to ensure that this finding is not only restricted to DAPI staining as well 
as to prove that mitotic catastrophe is induced in stilbene 5c-treated cells. Figure 14 demonstrates 
that treated cells have bi- and micronuclei with the presence of DNA fragments as an indication 
of mitotic catastrophe induction.  
 
3.6 Stilbene 5c induces p53-independent cell death 
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 Due to the appearance of multiple modes of cell death in HCT116 cells in response to 
stilbene 5c, we then sought to investigate the role of the wild-type p53 gene in HCT116 cells and 
the involvement of this protein in the antitumor action of stilbene 5c. The tumor suppressor gene 
p53 plays major roles in cell mechanisms that respond to a genotoxic stress such as the induction 
of cell cycle arrest at G1/S phase and the initiation of apoptosis signaling pathways. It has been 
widely known that cells lack wild-type p53 have the capability to evade apoptosis and become 
more likely to be resistant to anticancer therapy. Thus, one of the most desirable effects of an 
antitumor agent is to be working regardless p53 status since more than 50% of tumor cell lines 
are p53 mutant. In order to understand the function of p53 in our system, we treated HCT116 
(p53 -/-) cells with 100 nM stilbene 5c and evaluated the cell viability in a time course study.  
(p53 -/- HCT-116) cells showed equal sensitivity to stilbene 5c as in the p53 wild-type HCT-116 
cells, indicating that stilbene 5c does not require a wild-type p53 gene to produce its anticancer 
effect (Figure 16).  
 
3.7 Induction of autophagy in HCT116 (p53 -/-) and HCT116 (p53 +/+) cells 
 As we observed that stilbene 5c is also effective in p53-null HCT116 cells, we wanted to 
identify the early mode of cell death in those cells. Our previous results indicated that apoptosis 
was not evident in HCT116 (p53 +/+) cells until day 3. Therefore, it was important to perform 
similar studies in the p53 null cells using acridine orange staining to determine whether 
autophagy is induced in order to better understand the role of autophagy in our system. We found 
that extensive autophagy is promoted at the same extent in both p53-null and wild type cells 
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during the first three days (Figure 17). This finding may point toward the probability of 
autophagic cell death in HCT116 cells as a result of stilbene 5c treatment. 
 
3. 8 Low dose of stilbene 5c does not disrupt tumor vascularization and fails to inhibit metastasis 
of B16F10 melanoma cells in C57BL/6 mice 
 The effectiveness of stilbene 5c was also examined in B16F10 cells and was shown to 
promote cell death at concentrations of 30nM and 300nM in vitro (Figure 18). Both 
concentrations resulted in more than 90% of cell killing over a period of five days. B16F10 
melanoma cells showed sensitivity to the microtubule poison, JG-03-14, at concentrations of 250 
nM and 500 nM (Figure 19). Our studies further indicated that both stilbene 5c and JG-03-14 
induce autophagy and senescence, but not apoptosis in melanoma cells (Figure 20, Figure 21). 
We evaluated the effect of intraperitoneal administration of stilbene 5c and JG-03-14 at non-
toxic doses 25 mg/kg and 200 mg/kg, respectively. B16F10 melanoma cells were chosen for this 
assay due to the susceptibility of these cells to travel through the circulation and metastasize onto 
the lungs to form dark nodules. C57BL/6 mice were injected intravenously with B16F10 
melanoma cells and mice were then treated with 25 mg/kg/day five days a week for two weeks. 
In this study, neither stilbene 5c nor JG-03-14 prevented the invasion of B16F10 melanoma cells 
into the lungs according to the number of tumor nodules (64.375 ± 51.5 with vehicle, 83.25 ± 
55.257 with 25 mg/kg/day stilbene 5c and 52.125 ± 47.7 with 200 mg/kg/day JG-03-14; n=8) 
(Figure 22). We further measured the surface area of each nodule to assess whether stilbene 5c or 
JG-03-14 disrupts the vascular perfusion of the tumor. Lungs were sectioned at thickness of 4 
microns and embedded into Eosin and Hematoxylin and nodules sizes were measured and 
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analyzed. While JG-03-14 induced a significant decrease of average nodule size, our calculations 
revealed that a non-significant reduction in tumor volume resulted from the treatment with 
stilbene 5c (0.0518 mm3 ± 0.006416 with vehicle, 0.0403 ± 0.00972 with stilbene 5c, and 
0.02145 ± 0.004113 with JG-03-14, p = 0.0573, vehicle vs treated, n = 6) (Figure 24).  
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Figure Legends.  
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Figure 1. Sensitivity of HCT116 cells to stilbene 5c. Viability of HCT-116 colon cancer cells 
to stilbene 5c was measured by the MTT assay. 6000 cells were plated in 96-well plates and 
continuously exposed to the indicated concentrations of stilbene 5c for 72 hours. MTT dye was 
added to each well and cells were incubated for an additional 3 hours. DMSO was then used to 
dilute the precipitated MTT dye and the absorbance was read at wavelength 490 nM. This 
experiment was done in triplicate and error bars represent standard deviation (* p<0.05 compared 
to control)  
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2.                                                                                                    
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Figure 2. Determination of sensitivity to stilbene 5c based on clonogenic survival. HCT116 
cells were plated in 6-well plates and treated with the indicated concentrations for 48 hours. Drug 
was washed out and cells were supplemented with fresh medium every other day for an 
additional 7 days. Number of colonies in each well was counted and calculated as a percentage 
of control. This experiment was performed in triplicate and error bars represent standard 
deviation (* p<0.05 compared to control)  
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Figure 3. Time course study of HCT116 cells after continuous exposure to100 nM stilbene 
5c. HCT-116 cells were plated in 6-well plates and treated with 100 nM of stilbene 5c over a 
period of 5 days. Cells were harvested and collected and viable cell number was determined by 
trypan blue exclusion assay using the automated Countess cell counting device. Cells were plated 
in triplicate for each condition. This experiment was performed in different times (* p<0.05 
compared to control) 
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4.  
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Figure 4. Continous exposure to stilbene 5c leads to loss of proliferation. The time course 
study shown in figure 3 was extended for 10 more days post treatment. On day 5, the drug was 
removed and remaining cells were supplemented with fresh medium every other day until day 
15. At indicated time points, cells were harvested with trypsin and counted using trypan blue 
exclusion assay. This experiment was performed in triplicate.   
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Figure 5. Chronic treatment of 100 nM stilbene 5c promotes senescence in HCT116 colon 
carcinoma cells. HCT116 cells were plated in 6-well plates and exposed to 100 nM of stilbene 
5c. The drug was then removed and cells were incubated with staining buffer and X-gal for 
overnight. Using electron microscopy at the magnification power of 20X, the morphological 
markers of senescence were obvious with a remarkable increased blue color stain observed in 
treated cells. The result was confirmed by three different experiments.  
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Figure 6.  Assessment of induced senescence by quantification of β-galactosidase staining 
intensity in stilbene 5c-treated HCT116 cells. In addition to the classical microscopic method, 
induction of senescence could be assessed by flow cytometry to measure the fluorescence of β-
galactosidase staining and size of cells. Data presented in the graph were generated based on the 
percentage of cells that were positively stained with β-galactosidase in both treated and non-
treated conditions i.e cell population in P2 area of Panel A. In panel B, treated cells showed a 
rightward shift, indicating an increase in the size, complexity and granularity of treated cells. 
This experiment was performed in triplicate (* p<0.05 compared to control) 
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7.  
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Figure 7. Evaluation of autophagy induction by acridine orange staining. 
Cells were plated and treated with 100 nM of stilbene 5c. At indicated points, acridine orange diluted in 
medium in a ratio of 1:10000 was added to cells. During autophagy, acidic vacuoles are stained with 
acridine orange dye. Images were taken under a fluorescent microscope at a magnification power of 
200X. Three different experiments were performed to confirm the result.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44 
 
8.  
 
 
                                    Control        
 
 
                       
                              Day 3  
45 
 
 
 
 
 
 
 
 
 
 
 
0
5
10
15
20
25
30
35
Control St.5C 100nM
*
%
of
 A
.O
. 
Quantification of autophagy induced in HCT116 cells  in response to St. 5c 
46 
 
Figure 8. Quantification of intensity of autophagy by flow cytometry.  
Cells were treated with 100 nM stilbene 5c for 3 days. Cells were then harvested and centrifuged 
at 1500 rpm. Acridine orange was diluted in PBS in a ratio of (1:10000) and was then added to 
the cells for staining. The extent of autophagy was counted based on the number of cell 
population in quadrants Q2 and Q4 from our raw data.  This experiment was performed three 
times (* p<0.05 compared to control) 
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Figure 9. Stilbene 5c promotes the formation of red puncta with LC3-II in RFP-LC3 
HCT116 colon cancer cells. HCT116 cells were transfected with an RFP-LC3 vector and plated 
in 6-well plates. Cells were then treated with 100 nM stilbene 5c for up to 3 days. At each time 
point, drug was removed and cells were washed with sterile PBS. Images were taken under a 
fluorescent microscope with a magnification power of 20X. Cells undergoing autophagy are 
characterized by increased number and size of red puncta with a remarkable enlargement of 
cells.  
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Figure 10. Degradation of p62 protein after treatment of HCT116 cells with 100nM stilbene 5c. 
Completion of autophagy process was confirmed via the degradation of p62 by western blotting. 
HCT116 human colon cancer cells were treated with 100nM stilbene 5c for 24 and 48 hours and levels 
of p62 protein was measured. A clear degradation was obvious in response to 100nM stilbene 5c.  
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Figure 11. Assessment of apoptosis by detection of DNA fragmentation using the TUNEL assay.  
HCT116 colon carcinoma cells were exposed to 100 nM stilbene 5c for 3 days. Cells were then loaded 
on slides, stained by DAPI/TUNEL, and covered by cover slips. Images were taken under a fluorescent 
microscope using a magnification power of 200X. DAPI stain is used to localize the nuclei in both 
treated and non-treated cells. The fluorescent dots represent the fragmented sites on DNA, which are 
considered a hallmark of apoptosis. Two different experiments were performed to confirm the result.   
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Figure 12. Stilbene 5c induces apoptosis in HCT116 colon cancer cells.  
Cells were treated with 100 nM stilbene 5c for one, three, and five days and stained with Annexin V and 
PI to assess whether cells die via apoptosis and/or necrosis . The raw data show four quadrants; wherein, 
Q1 corresponds to necrotic cells only, Q2 reflects the late apoptotic cell population, Q3  indicates cells 
that neither apoptotic nor necrotic cells, and Q4 indicates early apoptosis. The percentage of apoptotic 
cells presented in Panel B is counted based on percentage of cells in both Q2 and Q4. This experiment 
was performed twice (* p<0.05 compared to control) 
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Figure 13.  Mitotic catastrophe is promoted in HCT116 cells in response to 100 nM stilbene 5c.  
HCT116 colon cancer cells were plated in 6-well plates and treated with the indicated concentration. At 
the indicated time points, drug was washed out and a dilution (1:10,000) of DAPI in PBS was added to 
stain the nuclei. Images were taken under a fluorescent microscope with magnification power of 200X. 
Markers of drug-induced mitotic catastrophe are characterized by bi-nucleated and micro-nucleated 
cells. This experiment was done in triplicate. 
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14.  
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Figure 14. Stilbene 5c – treated HCT116 cells undergo mitotic catastrophe cell death.  
Images shown in this figure represent HCT116 colon carcinoma cells treated with 100 nM stilbene 5c 
for three days. Cells were then collected and loaded on cover slips on which nuclei were stained with 
Hoechst dye. In control cells, nuclei are separated and well rounded; whereas, treated cells nuclei appear 
abnormal in size with more than one nucleus in the same proximity due to the failure to fall apart as well 
as clear bi-nucleation, indicating the induction of mitotic catastrophe. This experiment was performed 
twice.  
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Figure 15. Cell cycle analysis demonstrates growth and cell death in HCT116 colon cancer cells 
after exposure to 100 nM stilbene 5c. Cells were plated in 6-well plates and allowed to adhere 
overnight. Serum-deficient medium was added overnight to synchronize the cells at the same phase. On 
day 0, drug was added to treatment wells and control cells were supplemented with fresh medium. At 
each time point, cells were trypsinized and the experiment was performed as explained in chapter 2. 
Cells were arrested at the G2/M phase 24 hours post-treatment with an increase in the sub-G1 population 
in time-dependent manner. Images in the right column show the same distribution of cells but in 
normalized cell count (Y) axis. This experiment was performed twice.  
 
 
 
 
 
 
 
 
 
 
 
61 
 
 
16.  
            
  
 
 
 
 
 
 
62 
 
 
Figure 16. Similar response of p53-null HCT116 cells and p53-wt HCT116 cells to 100 nM stilbene 
5c.  
The p53-null HCT-116 cells were plated in 6-well plates and treated with 100 nM of stilbene 5c over a 
period of 5 days. Cells were harvested and collected and viable cell number was determined by trypan 
blue exclusion assay using the automated Countess cell counting device. Cells were plated in triplicate 
for each condition. This experiment was performed in three different times (* p<0.05 compared to 
control)  
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Figure 17. Promotion of autophagy in p53-null HCT116 colon cancer cells after exposure to 100 
nM stilbene 5c. Both p53-null and –wild type HCT116 colon cancer cells were plated in 6-well plates 
and treated with 100 nM stilbene 5c. At indicated time points, drug was removed and cells were stained 
with acridine orange for 15 minutes. Images were taken under a fluorescent microscope at magnification 
power of 20X. This experiment was performed in triplicate.  
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18.  
 
66 
 
Figure 18. Inhibition of colony formation in B16F10 melanoma cells by stilbene 5c.  
150 cells of B16F10 cells were plated per well in triplicate in 6 well plates. Control cells were 
seeded at the same density and allowed to incubate in drug free medium while cells treated with 
3nM, 30nM, 300nM and 1000nM stilbene 5c were incubated for 72 hours. Drug containing 
medium was removed at the end of the 72 hours and replaced with fresh medium. When colonies 
of at least 50 cells are visible to the naked eye, cells were stained with crystal violet and counted 
visually. The number of colonies formed decreased in a dose-dependent manner in cells treated 
with stilbene 5c compared to control cells. (# p<0.05 compared to control)  
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Figure 19. A dose-dependent decrease in colony formation in B16F10 in response to JG-03-
14.  
B16F10 cells were plated at a density of 100 cells/plate for DMSO, JG 10 nM and 500 cells/plate 
for JG 250 nM and JG 500 nM.  Assay shown is a representative experiment performed in 
triplicate that was corrected for plating efficiency. Two identical replicate experiments were 
performed for confirmation. Error bars represent standard deviations and significant differences 
from DMSO treatment are indicated by * (P<0.05)  
69 
 
20.  
             Stilbene 5c 300 nM                                                       JG-03-14 500 nM 
                                    
                     Control                                                                        Control  
                          
                     Day 3                                                                           Day 3 
  
70 
 
Figure 20. Stilbene 5c and JG-03-14 induce extensive autophagy in B16F10 melanoma cells.  
Acridine Orange staining was utilized to assess the induction of autophagy in B16F10 cells 
treated with 300nM stilbene 5c and 500nM JG-03-14. Cells were plated, incubated overnight and 
treated the following day with either 300nM stilbene 5c or 500nM JG-03-14. Acridine Orange 
images were taken using an inverted fluorescent microscope. Induction of autophagy was 
apparent due to the orange puncta distribution in the treated cells. 
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21.  
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Figure 21. JG-03-14 and stilbene 5c promote senescence in B16F10 melanoma cells.  
B16F10 cells were treated with 500nM JG-03-14 and 300 nM stilbene 5c for 72 hours in two 
individual studies. Drug was washed out and cells were stained with β-galactosidase as a marker 
of senescence. Images were taken at the magnification power of 200X. 
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Figure 22. Stilbene 5c did not suppress the metastasis of B16F10 melanoma cells in C57BL/6 mice. 
B16F10 melanoma cells that are syngeneic in C57BL/6 mice were injected intravenously. Drug was 
administered intraperitoneally once per day for five days a week over a period of two weeks. The 
vehicle used was a mixture of ethanol, tween and saline in a ratio of 2:1:7. Adriamycin was used as a 
positive control. The efficacy of drug was measured according to the number of dark nodules 
metastasized to the lungs. (* p<0.05 compared to control, n = 8) 
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23. Evaluation of the effect of stilbene 5c on tumor growth and vascular perfusion. The surface area 
of each nodule was measured by staining the tumor nodules with Hoechst stain. Images of the nodules 
were taken  microscopically and nanozoomer computer software (Olympus) was used to measure the 
surface area of each nodule. The average nodule size was calculated per mouse for six mice per each 
group. Non-significant reductions in the surface area   were induced by stilbene 5c.  
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Figure 24. Images of B16F10 tumor nodules metastasized to mice lungs. Lung tissues were paraffin 
embedded, sectioned at 4 microns thickness and stained with Hematoxylin and Eosin. Tumor nodules 
appear darker when stained with 1H&E. Also, dark nodules are considered cancerous as they show 
melanin pigments and abnormal nuclear shape when they were observed by nanozoomer computer 
software.   
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Chapter 4: Discussion 
4.1 Overview 
 Microtubles are dynamic proteins that play major functions in trafficking, signaling, division, 
and migration in eukaryotic and mammalian cells. These proteins are found in both interphase and 
dividing cells. Therefore, many microtubules inhibitors were developed and evaluated for their activity 
against multiple diseases such as malaria and cancer [78].  
Different microtubule poisons have been utilized to treat various forms of cancer. The 
mechanism of microtubule poisons’ action is thought to be by the alteration of microtubule dynamics. 
Vinca- and Colchicine-binding inhibitors destabilize microtubule depolymerization; while, taxanes 
increase polymerization at high doses. Vinca alkaloids and taxanes were discovered more than 40 years 
ago and have been used effectively in the treatment of different solid and haematological malignancies 
[79-81]. However, many colchicine-binding inhibitors have been screened in vitro, in vivo, and in 
clinical trials, but none of them has been clinically approved for any therapeutic indication yet due to 
their severe neuro- and crdiotoxicities [14]. Moreover, microtubule inhibitors appear to be active in 
disrupting tumor perfusion. These agents target tumor vascularization by the inhibition of proliferation 
and migration, key role functions of microtubule, of newly formed endothelial cells. Resistance to these 
agents can be developed by numerous mechanisms including cellular efflux of the drug, alterations at 
the binding site of the drug, and inability to induce apoptosis in treated cells. Previous studies of stilbene 
5c showed this drug disrupts tumor perfusion without affecting normal organ perfusion, leading to 
decrease of blood and oxygen to tumor cells [16]. Also, stilbene 5c was found to promote apoptosis in 
ovarian and leukemic cancer cells in vitro. [14-15]. In this study, we sought to evaluate the anticancer 
properties of stilbene 5c on HCT116 colon carcinoma cells and investigate induced modes of cell death.  
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4.2 Cell death  
 Initial experiments were designed to identify effective concentrations of stilbene 5c in HCT116 
cells.  Cells were treated with 10nM, 30nM, 100nM, 300nM, and 600nM of stilbene 5c. According to 
our observations in clonogenic survival assay,  100nM stilbene 5c  reduced the number of colonies 
formed by 90%.  This concentration of stilbene also induces cell death in HCT116 cells based on a  
reduction in cell viability  of approximately 75%. In both experiments, neither 10nM nor 30nM affected 
cellular proliferation or the number of colonies formed after the treatment compared to controls. This 
finding suggests that lower concentrations of stilbene 5c are not sufficient to inhibit colchicine-binding 
site on tubulin.  
HCT-116 cells were treated with 100nM stilbene 5c in order to understand the behavior of HCT116 cells 
post-treatment in a time course study. A time dependent decrease in cell viability was observed starting 
within 24 hours after treatment. Two days post-treatment, the remaining live cells underwent prolonged 
growth arrest for the remaining time course of the study. . The failure of re-growth appears to be 
irreversible due to the incapability of treated cells to reproduce after drug removal. This state of growth 
arrest demonstrates consistency with clonogenic survival assay findings, which might indicate that cells 
respond to stilbene 5c by undergoing senescence after cell death.  
4.3 Apoptosis  
 Previous studies of stilbene 5c in leukemia and ovarian cancer in vitro models revealed that cells 
die primarily through apoptosis [14-15]. As shown by time course study, extensive cell death occurs 
early after the exposure of HCT116 colon cancer cells to stilbene 5c. We have mentioned earlier that the 
deficiency in apoptotic signaling pathways can lead to the development of resistance to microtubule 
poisons. HCT116 colon cancer cells have a wild-type p53 protein and proficient caspase enzymes. All of 
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these facts indicated that it was of importance to investigate whether apoptosis represents a primary 
mode of cell death.  While there was no evidence of apoptosis within 24 hours post treatment, treated 
cells clearly showed an increase in apoptosis by 25% after 72 hours of exposure to the drug. This finding 
was confirmed by the TUNEL assay, where many nuclei had fragmented DNA. To further understand if 
the wild-type p53 plays a key role in the triggering of apoptosis in HCT116 cells in response to stilbene 
5c, we treated HCT116 p53 (-/-) cells, in which apoptosis signaling pathways activation are less likely to 
be induced, with the drug and monitored  cell viability over a period of 5 days. The p53-knock out cells  
responded similarly to stilbene 5c, sugesting that apoptosis is not primarily induced upon exposure to the 
drug. However,  p53-mediated apoptosis is triggered by DNA damaging agents [82], and the previous 
studies of stilbene 5c revealed that this drug does not have DNA damaging properties [14]. Thus, we 
conclude that stilbene 5c induces cell death in a p53-independent manner and that there are modes of 
cell death other than apoptosis induced in stilbene 5c-treated HCT116 cells.  
4.4 Mitotic catastrophe  
 Several antitumor agents, including microtubule poisons, can trigger mitotic spindle check points 
[83]. It has been shown that anti-microtubule agents induce mitotic arrest-associated cell death [84-85]. 
For instance, combretastatin A4, a colchicine-binding inhibitor, was found to promote a phenomenon of 
cell death related to mitotic catastrophe [86]. One of the interesting findings of previous stilbene 5c 
studies was that Chk2 deficient cells become more sensitive to stilbene 5c [14]. Some studies in the 
literature pointed out that activation of Chk2 proteins prevents the cell from entering the cycle by down-
regulating Cdc2/cyclin B complex [87]. According to this inhibitory effect of this protein, it is 
speculated that mitotic catastrophe can be negatively regulated by Chk2. Treatment of Hela cells with 
debromohymenialdisine (DBH), a chemical inhibitor of Chk2, led to the promotion of mitotic 
catastrophe associated with markers of apoptosis [65]. In our study, we found that some cells failed to 
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complete the process of cytokinesis when stained with DAPI. This observation appears consistent with 
the previous findings of the cytotoxic effect of stilbene 5c on ovarian cancer cells [14]. Also, Hoechst 
staining confirmed that prolonged treatment of HCT116 cells results in frequent multiple micronuclei, a 
hallmark of mitotic catastrophe. These observations may indicate that the early seen cell death is 
generally not due to apoptosis, but rather through mitotic catastrophe. However, recent reports have 
shown that mitotic catastrophe characterizes another form of apoptosis [65, 77]. Other reports indicated 
that apoptosis becomes initiated after the slippage of cells from mitotic catastrophe [84, 88]. Moreover, 
several in vivo and in vitro studies have indicated that mitotic catastrophe is associated with the release 
of pro-apoptotic proteins and activation of caspases, which suggests that induction of mitotic catastrophe 
requires some pathways involved in mechanisms of apoptosis [64-66] This might explain why markers 
of apoptosis appear three days after the treatment with stilbene 5c.  
Treatment of p53-null HCT116 cells resulted in a decrease in cell viability to an extent similar to that 
observed in the wild type p53 HCT116 cells. Some reports have argues that the p53 gene is required to 
induce apoptosis or senescence, but not the mitotic catastrophe [71]. Moreover, it has been thought that 
cells lacking functional p53 protein undergo forms of cell death rather than apoptosis such as mitotic 
catastrophe and necrosis [63]. Taken together, we conclude that HCT116 cells may primarily undergo 
mitotic catastrophe in response to the treatment with stilbene 5c. As a result, apoptosis appears after the 
promotion of mitotic catastrophe due to the cross-talk between these processes.  
 
4.5 Induction of autophagy  
 Autophagy is a catabolic process in which the cell’s contents are broken down by lysosomal 
degradation. It is established that HCT116 colon carcinoma cells have constitutively active PI3K and ras 
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mutant genes [89]. A study by Gou et al proved that cells with a mutated ras gene, including HCT116 
cells, require autophagy to survive [71]. Thus, HCT116 cells have a relatively high basal level of 
autophagy. Until today, it is still ambiguous what amount of autophagy is needed to induce cell death. 
Also, it is still indistinguishable what signaling elements are responsible for the promotion of autophagic 
cell death rather than cytoprotective autophagy. One of the suggested mechanisms by which autophagy 
becomes initiated is through the interaction with microtubules. Although the function of microtubules in 
the induction of autophagy is not well understood, some studies have shown that microtubules play a 
role in autophagosomal formation [90]. The same study demonstrated that autophagosomal level was 
increased by more than two fold when cells were treated with vinblastine [84]. In contrast, drugs 
stabilizing microtubule polymerization, such as paclitaxel, failed to increase acidic vacuoles. These 
results may indicate that microtubules are not essential for autophagosome development, but at least can 
contribute to the increase of amount of autophagosomes. Our observations suggest that the obvious 
increase in the amount of acidic vacuoles in response to stilbene 5c may be due to its effects on 
microtubule dynamics.   
 Induction of autophagy was confirmed by monitoring microtubule associated protein light chain 
LC3 expression in HCT116 cells. LC3-II, a marker of autophagy, is produced by proteolytic cleavage of 
LC3-I, and required for the formation of autophagosomes [91]. We found that stilbene 5c increased the 
number of RFP punctate pattern in treated cells as early as day 1 compared to control. This finding 
supports the idea that autophagy is initiated earlier than other modes of cell death. More importantly, 
acridine orange and RFP-LC3 transfection only indicate the induction of autophagy but not the 
completion of this process. Thus, another experimental technique has been used as an indicator for 
autophagic flux. We have monitored the level of p62 after the incubation of HCT116 cells with stilbene 
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5c as early as day 1. We found a clear degradation of p62 after the treatment, indicating that autophagy 
has been going to completion.  
 A recent study showed that curcumin induces autophagy in HCT116 cells in both p53-wild type 
and p53-deficient HCT116 cells [92]. Consistent with this finding, we have found that p53-null HCT116 
cells incubated with stilbene 5c expressed a similar extent of autophagy as the p53-wild type HCT116 
cells. This result strongly suggests that stilbene 5c promotes autophagy in a p53-independent manner, 
and may also lead to autophagic cell death.  
 Although the cross-talk between autophagy and apoptosis is not very well understood, an 
interaction between apoptosis and autophagy has been illustrated by many studies.  A study by Ding et 
al indicating that Bax-positive HCT116 cells undergo autophagic cell death followed by apoptosis [93]. 
In the same study, it was found that inhibition of autophagy led to apoptosis in Bax-proficient HCT116 
cells but not the Bax-deficient HCT116 cells, indicating that presence of Bax is important for switching 
the mode of cell death to apoptosis. Another study by Yousefi et al demonstrated that the overexpression 
of the ATG5 gene in human cancer cells enhances their sensitivity to undergo autophagic cell death 
followed by apoptosis when treated with ceramide or DNA-damaging agents [94]. In this study, when 
the ATG5 gene was knocked out, the susceptibility of these cells to die through autophagy was 
eliminated with a significant reduction in apoptotic markers. This linkage between autophagy and 
apoptosis can possibly be due to the cleavage of ATG5. When the cell becomes exposed to excessive 
autophagic stress, calpain proteins cleave ATG5 to produce a fragment that loses its autophagy-
promoting activity and gains its pro-apoptotic activity [94]. This released fragment translocates into the 
mitochondria, where it binds to BCL-XL proteins and promote apoptosis. Also, there is another 
mechanism by which the ATG5 protein switches mode of cell death from autophagy to apoptosis. ATG5 
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gene can bind to FADD (Fas-associated via death domain) via its C terminus, which in turn stimulates 
caspase-dependent apoptosis [95]. 
 In our results, we found that apoptosis was preceded by induction of both autophagy and mitotic 
catastrophe. We have discussed the possibility of how mitotic catastrophe leads to the induction of 
apoptosis. Here, we show another possibility where triggered autophagy can eventually lead to apoptotic 
cell death. For this reason, we expect that autophagy has the capacity to be cytotoxic in this system more 
than being cytoprotective. This finding can be of clinical utility, since some tumor cells have the ability 
to evade apoptosis. thereby showing resistance to the currently used therapeutics [41, 82].  
4.6 Senescence 
 Several studies have shown that induction of autophagy is associated with promotion of 
senescence in cancer cells [74, 92]. Lu et al found that autophagic cell death led to growth arrest in a 
xenograft model of ovarian cancer cells [96]. Also, the inhibition of autophagy was found to delay, but 
not completely inhibit, the induction of cellular senescence after  exposure to an antitumor agent [70, 
89]. It appears that autophagy plays a dual role either to induce senescence or promote apoptosis in 
response to the treatment with stilbene 5c. Due to this linkage between both these phenomena, we 
anticipate that the promotion of autophagy in stilbene 5c-treated HCT116 cells may lead cells to transit 
into senescence. Our time course treatment studies showed that treated cells apparently undergo a state 
of growth arrest initiated two days post treatment. In addition, cell cycle analysis revealed a growth 
arrest at phase G2/M within 24 hours post treatment, with cell killing represented by a sub-G1 
population. Also, our β-galactosidase staining indicated that the surviving population showed signs of 
senescence following induced autophagy, as cells were enlarged and flattened. Taking into account that 
tumor cells need to evade the step of senescence to maintain growth [97], we found that the residual 
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surviving cells failed to recover after  replenishment with drug-free medium for 15 days in an extended 
proliferative recovery study. All of these findings point toward an additional potential therapeutic 
outcome of stilbene 5c, preventing the re-growth of cancer cells after exposure.   
4.7 Antimetastatic and vascular disrupting properties of stilbene 5c 
 Beside their roles in cell division and proliferation, microtubules play major functions in 
trafficking and migration in mammalian cells. Metastasized tumor cells require migration of cancer cells 
and formation of new blood vessels to enrich the tumor site with blood supply and oxygen for growth 
and development. Both of these processes are essentially mediated by microtubules and can be easily 
distorted by targeting tumor vasculature [98]. Several antiangiogenic studies have shown that these 
functions were abrogated by microtubule poisons [99-100]. In addition, two well-known colchicine-
binding inhibitors have been identified as vascular-disrupting agents [101]. Another study indicated that 
stilbene 5c, a colchicine-site inhibitor, disrupts tumor vascular perfusion, but not the normal organ’s 
blood supply [16]. In this regard, we have studied the antiangiogenic and antimetastatic properties of 
stilbene 5c and JG-03-14, microtubule poisons that bind to the colchicine-binding site, on B16/F10 
melanoma in a syngeneic mouse model.  While neither stilbene 5c nor JG-03-14 showed an 
antimetastatatic effect according to the number of tumor nodules on the lungs,  JG-03-14, but not the 
stilbene 5c, significantly reduced the volume of these nodules, indicating that JG-03-14 disrupts the 
vascular perfusion of tumor. Although the effect of stilbene 5c was barely remarkable but non-
significant, we anticipate that higher doses of stilbene 5c are likely to disrupt tumor perfusion. The 
reason why JG-03-14 showed a significant effect could be due to either the higher dose used compared 
to stilbene 5c,  or different pharmacokinetic properties. . This finding may indicate that both JG-03-14 
and stilbene 5c are specific for angiogenesis via targeting endothelial cells as shown with 
combretastatin, an agent of the same group [16, 102].  
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4.8 Future studies  
 Our results showed that the drug stilbene 5c induces multiple modes of cell death and growth in 
HCT116 colon carcinoma cells. These results led us to the next aims of this study in which inhibitors of 
autophagy and apoptosis can be used to investigate what modes of cell death are essentially induced. To 
further explain what primary cell killing mechanisms are responsible for the effects of stilbene 5c, we 
can utilize select pharmacological agents to inhibit the process of autophagy and determine how this 
would influence   the toxicity of  stilbene 5c.  Chloroquine and Bafilomycin A-1 have been used to 
inhibit  fusion of the autophagosome and lysosomes, preventing the last step of autophagy [103]. Also, 
we can transiently silence essential autophagy-regulating genes such as ATG5, ATG7, and Beclin-1. 
However, these approaches to inhibit autophagy  might not  clarify the exact role of autophagy due to 
the appearance of other mechanisms of cell death concurrently with autophagy i.e. shutting down one 
mechanism will enforce cells to die via another pathway.  
In additional experiments, use of inhibitors of of caspase cleavage, which would block the 
induction of apoptosis, could identify the contribution of apoptosis to drug action. Based on our results, 
we found that apoptosis was induced after the appearance of other modes of cell death. This may 
illustrate for us that promotion of apoptosis is a consequence of excessive stress. Thus, using Z-Vad may 
allow us to differentiate between cytotoxic and cytoprotective roles of autophagy in HCT116 cells.  
 It would be useful if we also assessed apoptotic cell death and mitotic catastrophe in p53-null 
HCT116 cells. We found that stilbene 5c induces both cell death and autophagy in p53-knock out 
HCT116 cells. We can perform DAPI and TUNEL assays to assess apoptotic cell death in p53-defecient 
cells. However, Annexin V staining could be useful to quantify numbers of cells undergoing apoptosis. 
Moreover, it would be worthwhile to perform Hoechst staining to evaluate the intensity of mitotic 
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catastrophe induction in p53 (-/-) HCT116 cells. These suggested assays and studies may clearly answer 
the question of what primary modes of cell death are particularly induced by stilbene 5c.  
 Finally, we would evaluate the effectiveness of stilbene 5c on HCT116 colon cancer cells in 
vivo, using an orthotopic model [104]. In the previous studies of stilbene 5c, the drug showed   efficacy 
against HL60 and U937 cells in vivo [15]. IV injections of this drug at doses of 10, 50, and 100 mg/kg 
resulted in 22, 62 and 58% apoptosis respectively. In addition, 100 mg/kg of drug extensively killed 
central tumor cells with permitting the survival of viable cells at the peripheral areas of the tumor [16]. 
In this in vivo study, stilbene 5c was found to be tolerated in mice at doses as high as 100 mg/kg, 
indicating that stilbene 5c could be a promising VDA due to its low cardiotoxicity. Taken together, the 
anti-proliferative and the vascular disrupting properties may suggest that stilbene 5c is an effective agent 
for the therapy colon cancer.  
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